Entreprise · 10/05/19941 min de lecture
Prospective Grant of Exclusive License: Anti-viral Agents F-ddA and F-ddI Useful in the Treatment of Acquired Immunodeficiency Syndrome (AIDS)
Traduction automatique locale · Langue originale de la source
Résumé
This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent Application SN 07/762,082 (FWC of 07/288,652, CIP of 07/ 039,402) entitled ``Acid Stable Purine Dideoxynucleosides Active Against The Cytopathic Effects Of Human Immunodeficiency Virus'' and U.S. Patent Application SN 07/556,713 entitled ``2'-Fluorofuranosyl Derivatives And Novel Method Of Preparing 2'-Fluoropyrimidine and 2'- Fluoropurines'' and corresponding foreign patent applications to U.S. Bioscience, Inc. of West Conshohocken, Pennsylvania. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to the field of treatment of human immunodeficiency virus (HIV) infection in humans using 9-(2,3 dideoxy-2-fluoro- -Dthreo-pentofuranosyl)-adenine (F-ddA) and 9-(2,3 dideoxy-2fluoro- -D-th